White Paper

Delivering On The Promise Of Bispecifics: State-Of-The-Art Bispecific Antibody Development

By Séverine Fagète, Leslie S. Wolfe, Niket Bubna, and Sigma S. Mostafa

GettyImages-1358868801-antibody-virus-pathogen-cell

Bispecific antibodies (bsAbs) have transformed the field of immunotherapy. However, moving these life-changing therapeutics from the bench to the clinic can be time-consuming and costly. Further, challenges such as aggregation, degradation, fragmentation, and denaturation may ultimately hinder a program from advancing to the clinic. Partnering with a CDMO with relevant experience and technologies can be critical for safely and cost-effectively manufacturing bispecific antibodies.

With Selexis’s cell line technology and KBI Biopharma’s manufacturing and analytics, we lead the industry in technologies and expertise for efficiently producing bispecific therapeutics for clinical use. The promise of this class of therapeutics is huge, and we are driven to help our clients rapidly advance the clinical development of these new and powerful treatment options for patients who live with cancers and other serious diseases.

VIEW THE WHITE PAPER!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online